[go: up one dir, main page]

MX2014000292A - Usos de inhibidores etiquetados hsp90. - Google Patents

Usos de inhibidores etiquetados hsp90.

Info

Publication number
MX2014000292A
MX2014000292A MX2014000292A MX2014000292A MX2014000292A MX 2014000292 A MX2014000292 A MX 2014000292A MX 2014000292 A MX2014000292 A MX 2014000292A MX 2014000292 A MX2014000292 A MX 2014000292A MX 2014000292 A MX2014000292 A MX 2014000292A
Authority
MX
Mexico
Prior art keywords
hsp90 inhibitors
labeled hsp90
hsp90
inhibitors
labeled
Prior art date
Application number
MX2014000292A
Other languages
English (en)
Inventor
Gabriela Chiosis
Mary L Alpaugh
Pillarsetty Nagavarakishore
Jason S Lewis
Steven M Larson
Taldone Tony
M Gomes-Dagama Erica
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of MX2014000292A publication Critical patent/MX2014000292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G01N33/575—
    • G01N33/57505—
    • G01N33/57557—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a diversos métodos de uso de inhibidores etiquetados HSP90 para mejorar el tratamiento de pacientes con cáncer con inhibidores HSP90, incluyendo métodos ex vivo e in vivo para determinar si un tumor responderá probablemente a la terapia con un inhibidor HSP90.
MX2014000292A 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90. MX2014000292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08
PCT/US2012/045861 WO2013009655A2 (en) 2011-07-08 2012-07-06 Uses of labeled hsp90 inhibitors

Publications (1)

Publication Number Publication Date
MX2014000292A true MX2014000292A (es) 2015-03-06

Family

ID=47506428

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000292A MX2014000292A (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90.
MX2014000286A MX347607B (es) 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014000286A MX347607B (es) 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados.

Country Status (13)

Country Link
US (4) US9555137B2 (es)
EP (3) EP3709022A1 (es)
JP (4) JP6054389B2 (es)
KR (2) KR102025142B1 (es)
CN (3) CN109374889B (es)
AU (3) AU2012282905B8 (es)
BR (1) BR112014000445A2 (es)
CA (2) CA2841173C (es)
DK (1) DK2729806T3 (es)
EA (1) EA201490230A1 (es)
ES (2) ES2766623T3 (es)
MX (2) MX2014000292A (es)
WO (2) WO2013009657A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP6054389B2 (ja) * 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたｈｓｐ９０阻害剤の使用
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
EP2972394A4 (en) * 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
CA2923829A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
JP6491214B2 (ja) * 2013-12-23 2019-03-27 メモリアル スローン ケタリング キャンサー センター 放射性標識のための方法および試薬
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
MA47474A (fr) 2015-10-05 2019-12-25 Memorial Sloan Kettering Cancer Center Polythérapie rationelle pour le traitement du cancer
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US11680283B2 (en) 2017-09-22 2023-06-20 University Of Washington In situ combinatorial labeling of cellular molecules
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
CN111499641B (zh) 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
CA3127237A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) * 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
JP7589935B2 (ja) * 2019-10-31 2024-11-26 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
EP4204561A4 (en) * 2020-10-02 2025-02-26 The Trustees Of Dartmouth College METHODS AND MEANS FOR THE TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASES AND FOR THE EVALUATION
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
EP1457499A1 (en) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US20070178537A1 (en) * 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
EA009920B1 (ru) 2003-08-29 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения пиримидотиофена
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
CN104531529A (zh) * 2003-10-31 2015-04-22 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
US9403828B2 (en) * 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US20090221010A1 (en) * 2005-10-21 2009-09-03 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
WO2007139955A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007269144B2 (en) 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US8580519B2 (en) * 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
AU2008240209A1 (en) * 2007-04-13 2008-10-23 Pharmacyclics, Inc. Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase
EP2200653A2 (en) 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
AU2008310664A1 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
US20090149397A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
ES2589403T3 (es) 2009-10-07 2016-11-14 Sloan Kettering Institute For Cancer Research Derivados de purina útiles como inhibidores de HSP90
JP2013510585A (ja) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
EA201391334A1 (ru) 2011-04-05 2014-06-30 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч Ингибиторы hsp90
EA201391587A1 (ru) 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Комбинированная терапия на основе hsp90
JP6054389B2 (ja) * 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたｈｓｐ９０阻害剤の使用
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
WO2015089402A1 (en) 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy

Also Published As

Publication number Publication date
EP3208615A3 (en) 2017-11-01
EP3208615A2 (en) 2017-08-23
KR102025142B1 (ko) 2019-09-26
AU2017204369A1 (en) 2017-07-20
WO2013009655A2 (en) 2013-01-17
CA2841173A1 (en) 2013-06-17
EP3208615B1 (en) 2019-10-09
EP2729806B1 (en) 2017-02-22
CN104081206B (zh) 2017-06-09
JP6662759B2 (ja) 2020-03-11
KR20170042805A (ko) 2017-04-19
JP2017121233A (ja) 2017-07-13
US20140242602A1 (en) 2014-08-28
AU2012282905B8 (en) 2017-08-31
AU2017204369B2 (en) 2019-08-01
JP2014527620A (ja) 2014-10-16
CN109374889B (zh) 2022-04-19
CA2841069C (en) 2021-11-23
EP2729806A4 (en) 2015-04-01
BR112014000445A2 (pt) 2017-06-27
AU2012282905A8 (en) 2017-08-31
JP2014525908A (ja) 2014-10-02
MX2014000286A (es) 2015-03-06
WO2013009657A1 (en) 2013-01-17
CN104081206A (zh) 2014-10-01
WO2013009655A3 (en) 2013-05-10
CA2841069A1 (en) 2013-01-17
NZ620634A (en) 2016-07-29
MX347607B (es) 2017-05-04
ES2766623T3 (es) 2020-06-12
CN109374889A (zh) 2019-02-22
EA201490230A1 (ru) 2014-06-30
ES2624982T3 (es) 2017-07-18
JP2019194232A (ja) 2019-11-07
JP6054389B2 (ja) 2016-12-27
EP3709022A1 (en) 2020-09-16
US11607465B2 (en) 2023-03-21
AU2012282903A1 (en) 2014-02-13
EP2729806A1 (en) 2014-05-14
HK1243175A1 (en) 2018-07-06
US20210138091A1 (en) 2021-05-13
CN104081203B (zh) 2018-07-31
JP6218147B2 (ja) 2017-10-25
KR102138218B1 (ko) 2020-07-28
US9555137B2 (en) 2017-01-31
AU2012282905B2 (en) 2017-04-06
US20140294725A1 (en) 2014-10-02
CA2841173C (en) 2022-06-21
CN104081203A (zh) 2014-10-01
KR20140075667A (ko) 2014-06-19
AU2012282905A1 (en) 2014-02-13
US20240058482A1 (en) 2024-02-22
DK2729806T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CY1116703T1 (el) ΧΡΗΣΗ sGC ΔΙΕΓΕΡΤΩΝ, sGC ΕΝΕΡΓΟΠΟΙΗΤΩΝ, MOΝΩΝ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΗΣ ΣΥΣΤΗΜΙΚΗΣ ΣΚΛΗΡΥΝΣΗΣ (SSc)
EA201171367A1 (ru) Винилиндазолильные соединения
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
EA201391208A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
MX2015011753A (es) Metodos para tratar cancer de vegija.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
EA201400178A1 (ru) Лечение рака молочной железы
CL2012003385A1 (es) Tratamiento para la incontinencia.
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
MX2011010955A (es) Terapia complementaria contra el cancer.
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma